Cite
HARVARD Citation
Danese, S. et al. (n.d.). DOP42 Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study. Journal of Crohn's and colitis. pp. i091-i092. [Online].